Aubagio vs Ocrevus
Side-by-side cost comparison based on Medicare Part D data
Aubagio
Teriflunomide
Manufactured by Sanofi
Ocrevus
Ocrelizumab
Manufactured by Genentech/Roche
Aubagio costs 86% less per claim than Ocrevus ($3,363.00 vs $23,635.00). A generic version of Aubagio is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Aubagio | Ocrevus |
|---|---|---|
| Avg Cost Per Claim | $3,363.00 | $23,635.00 |
| Total Medicare Spending | $1.3B | $3.5B |
| Total Beneficiaries | 34,000 | 62,000 |
| Total Claims | 386,000 | 148,000 |
| Annual Cost/Patient | $38,176.00 | $56,419.00 |
| Year-over-Year Change | -5.6% | +16.5% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Sanofi | Genentech/Roche |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Teriflunomide | Ocrelizumab |
Aubagio vs Ocrevus: What the Data Shows
Aubagio (Teriflunomide) and Ocrevus (Ocrelizumab) are both used to treat multiple sclerosis. Based on Medicare Part D data, Aubagio costs $3,363.00 per claim, which is 86% less than Ocrevus at $23,635.00 per claim.
Medicare spent $1.3B on Aubagio and $3.5B on Ocrevus. In terms of patient reach, Ocrevus serves more beneficiaries (62,000 vs 34,000).
Year-over-year spending changed -5.6% for Aubagio and +16.5% for Ocrevus. Ocrevus saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Aubagio is cheaper at $3,363.00 per claim, compared to $23,635.00 for Ocrevus. That makes Aubagio about 86% less expensive per claim based on Medicare Part D data.
Yes, both Aubagio and Ocrevus are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Teriflunomide and generic Ocrelizumab can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $1.3B on Aubagio covering 34,000 beneficiaries, and $3.5B on Ocrevus covering 62,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Aubagio and Ocrevus on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.